There’s good evidence to support the use of romosozumab (Evenity) to reduce fracture risk in postmenopausal women with osteoporosis, a German quality group reports.
In an early benefit assessment, romosozumab treatment followed by alendronic acid (such as Fosamax) had only positive effects when compared with treatment by alendronic acid alone, the Institute for Quality and Efficiency in Health Care announced Monday. Among more than 4,000 study participants, there was considerable added benefit for reducing vertebral fracture risk in particular, it reported.
“There were fewer vertebral fractures and fewer other typical fractures in postmenopausal women with severe osteoporosis at high risk of fracture,” the group concluded.
In Germany, new drugs are subject to an assessment that examines whether the drug has an added benefit compared with other therapies.
Romosozumab was approved by the U.S. Food and Drug Administration in April 2019.
